Stem Cell Derived Pancreatic Islet Cell Treatment Shows Promise for Type-I Diabetes Mellitus

Published 2023-07-03

Investigators from the University of Toronta released some early data of a Phase 1/2 clinical trial investigating the safety and early efficacy of VX-880 a stem cell derived pancreatic islet cell product. All 6 adult patients with Type-1 Diabetes Mellitus who underwent treatment with VX-880 showed restored insulin secretion, improved glucose control and either reduction or elimination of the need for insulin dosing. Two patients with 12 months follow-up were insulin independent and no longer met criteria for Diabetes Mellitus.